RHEL — Rhelion Life Sciences Share Price
Last trade - 00:00- CA$15.35m
- CA$7.90m
- CA$4.20m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.82 | ||
| Price to Tang. Book | 1.31 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.98 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -37.3% | ||
| Return on Equity | -36.86% | ||
| Operating Margin | -223.47% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 2.33 | 3.95 | 4.75 | 4.94 | 4.2 | n/a | n/a | 106.79% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rhelion Life Sciences Corp., formerly Red Light Holland Corp., is a science and research led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary Filament Health Corp., the Company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with institutions around the world. PEX010 is its standardized natural psilocybin drug candidate, studied across 80+ clinical trials worldwide, including FDA-authorized programs in depression, PTSD, cancer-related distress, and substance use disorders. Its products also include IBEXX and MB2500. IBEXX is its botanical ibogaine drug candidate. MB2500 is its whole-leaf coca extract drug candidate. It also operates in the Netherlands' legal adult-use market and supports voluntary data collection and research to help advance the scientific understanding of natural psychedelics.
Directors
- Last Annual
- March 31st, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- April 24th, 2020
- Public Since
- May 28th, 2020
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 614,124,756
- Address
- 1 Adelaide Street East, Suite 801, TORONTO, M5C 2V9
- Web
- https://redlight.co/
- Phone
- +1 6042047129
- Auditors
- CLEARHOUSE LLP
Latest News for RHEL
Upcoming Events for RHEL
Q2 2027 Rhelion Life Sciences Corp Earnings Release
Q3 2027 Rhelion Life Sciences Corp Earnings Release
Similar to RHEL
Adaptogenics Health
Canadian Securities Exchange
Affinor Growers
Canadian Securities Exchange
Boosh Plant Based Brands
Canadian Securities Exchange
Britannia Life Sciences
Canadian Securities Exchange
Else Nutrition Holdings
Canadian Securities Exchange
FAQ
As of Today at 05:00 UTC, shares in Rhelion Life Sciences are trading at CA$0.03. This share price information is delayed by 15 minutes.
Shares in Rhelion Life Sciences last closed at CA$0.03 and the price had moved by -16.67% over the past 365 days. In terms of relative price strength the Rhelion Life Sciences share price has underperformed the Toronto Stock Exchange 300 Composite Index by -30.07% over the past year.
The overall consensus recommendation for Rhelion Life Sciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreRhelion Life Sciences does not currently pay a dividend.
Rhelion Life Sciences does not currently pay a dividend.
Rhelion Life Sciences does not currently pay a dividend.
To buy shares in Rhelion Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.03, shares in Rhelion Life Sciences had a market capitalisation of CA$15.35m.
Here are the trading details for Rhelion Life Sciences:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: RHEL
Based on an overall assessment of its quality, value and momentum Rhelion Life Sciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Rhelion Life Sciences is CA$0.12. That is 380% above the last closing price of CA$0.03.
Analysts covering Rhelion Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rhelion Life Sciences. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -41.24%.
As of the last closing price of CA$0.03, shares in Rhelion Life Sciences were trading -10.51% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Rhelion Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Rhelion Life Sciences' directors